Shares of Dendreon (DNDN +8.8%) extend their amazing three-day run, up nearly 80% since...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Shares of Dendreon (DNDN +8.8%) extend their amazing three-day run, up nearly 80% since pre-announcing better-than-expected Q4 revenue and revealing growing sales of its Provenge prostate cancer therapy. Too much too fast? William Blair's Katherine Xu “continue[s] to be concerned with Provenge’s eventual potential and profitability."